Clinical trials: Adrenocortical Carcinoma
Cushings Disease
Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease
The main purpose of this prospective, multicenter, open-label phase II study, was to evaluate the efficacy and safety of pasireotide alone or in combination with cabergoline in patients with Cushing's disease.
- Trial name
- NCT01915303
- Testing
- Pasireotide with or without cabergoline
- Where
- 29 sites in United States, Argentina and 14 more
- Volunteers
- 68 people
- Sponsor
- Novartis Pharmaceuticals
Adrenal Adenoma, Cushing Syndrome
A Prospective Cohort Study for Patients With Adrenal Diseases
The purpose of this study is to investigate the pathologic features, complications, and prognostic factors of functioning adrenal adenoma and suggest follow-up algorithms for adrenal incidentaloma.
- Conditions
- Adrenal Adenoma, Cushing Syndrome, Pheochromocytoma, Adrenal Incidentaloma
- Trial name
- NCT03474237
- Testing
- Hormone study and Imaging study
- Where
- South Korea
- Volunteers
- 1,500 people
- Sponsor
- Seoul National University Hospital
Adrenocortical Carcinoma
Natural History and Tissue Acquisition Study of Adrenocortical Carcinoma
Background: Adrenocortical carcinoma (ACC) is a rare tumor with an incidence of 1.5 to 2 per million people per year. It has a very poor prognosis with an overall 5-year mortality rate of 75 - 90% and an average survival from the…
- Trial name
- NCT02015026
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Cushing's Syndrome
Study to Evaluate CORT125134 in Participants With Cushing's Syndrome
Cushing's syndrome is a relatively rare disorder caused by prolonged exposure to high levels of the glucocorticoid hormone cortisol. Cushing's syndrome may result from elevated endogenous or exogenous sources of cortisol.
- Trial name
- NCT02804750
- Testing
- CORT125134
- Where
- 25 sites in United States, Hungary and 3 more
- Volunteers
- 35 people
- Sponsor
- Corcept Therapeutics
Adrenal Gland Neoplasms
Towards an Easy-to-use Adrenal Cancer/Tumor Identity Card
Malignant pheochromocytoma/paraganglioma (MPP) and adrenocortical carcinoma (ACC) are two rare cancer entities with a very unfavorable prognosis.
- Trial name
- COMETETACTIC (NCT02672020)
- Testing
- omics identity card
- Where
- 21 sites in France
- Volunteers
- 448 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Adrenal Tumor, Adrenal Mass
Prevention of Conversion in Posterior Retroperitoneal Adrenalectomy by Measuring Preoperative Anatomical Conditions
With our retrospective study the investigators show the limitations of the posterior retroperitoneal adrenalectomy by analyzing anatomical parameters.
- Conditions
- Adrenal Tumor, Adrenal Mass, Pheochromocytoma, Conn Adenoma
- Trial name
- NCT04071561
- Testing
- Posterior retroperitoneal adrenalectomy (PRA), Lateral transperitoneal adrenalectomy (LTA)
- Where
- Switzerland
- Volunteers
- 14 people
- Sponsor
- University of Basel
Adrenocortical Carcinoma, Peritoneal Carcinomatosis
Surgery and Heated Chemotherapy for Adrenocortical Carcinoma
Background: Adrenocortical carcinoma (ACC) is a rare tumor of the adrenal gland. Few people who develop this disease live more than 5 years after being diagnosed.
- Trial name
- NCT01833832
- Testing
- Cisplatin, Cytoreductive surgery, sodium thiosulfate
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Cancer Institute (NCI)
Adrenocortical Carcinoma
Sunitinib in Refractory Adrenocortical Carcinoma
Although a first randomized trial in patients with advanced ACC leading to the establishment of a first line cytotoxic chemotherapy is ongoing (FIRM-ACT), the failure rate even of this FIRM-ACT study is most likely clearly above…
- Trial name
- SIRAC (NCT00453895)
- Testing
- Sunitinib
- Where
- 2 sites in Germany
- Volunteers
- 39 people
- Sponsor
- University of Wuerzburg
Cancer, Neuroendocrine Tumors
A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients
This study will be a Phase I/II, open-label, non-randomized, dose-finding trial conducted at multiple clinical centers. The study is designed to determine the safety, tolerability and PK of TKM-080301 in adult patients with solid…
- Conditions
- Cancer, Neuroendocrine Tumors, NET, Adrenocortical Carcinoma
- Trial name
- NCT01262235
- Testing
- TKM-080301
- Where
- 8 sites in United States
- Volunteers
- 68 people
- Sponsor
- Arbutus Biopharma Corporation
Advanced Solid Tumors Cancer
A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)
This is an open-label, Phase I, dose-escalation study to determine the maximum tolerated dose (MTD) and the recommended phase two dose (RPTD), and to assess the safety, preliminary efficacy, and pharmacokinetic (PK) profile of…
- Trial name
- NCT03145909
- Testing
- ABBV-176
- Where
- 11 sites in United States, Australia and 2 more
- Volunteers
- 19 people
- Sponsor
- AbbVie
Colorectal Cancer, Pancreatic Adenocarcinoma
Circulating Tumor DNA Exposure in Peripheral Blood
This is a prospective, multi-center, blinded feasibility study. The objective of this study is to test the feasibility of the detection of tumor DNA of a variety of tumors in peripheral blood using a novel process for the…
- Conditions
- Colorectal Cancer, Pancreatic Adenocarcinoma, Gastric Cancer, Hepatocellular Carcinoma
- Trial name
- NCT03517332
- Where
- 6 sites in United States, Switzerland
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Quantgene Inc.
Pituitary Neoplasm, Pituitary Adenoma
Rhinological Outcomes in Endonasal Pituitary Surgery
This is a prospective, multi-center observational study designed to address patient-reported nasal outcomes in adults undergoing endoscopic and microscopic surgical removal of pituitary tumors.
- Conditions
- Pituitary Neoplasm, Pituitary Adenoma, Prolactinoma, Cushings Disease
- Trial name
- NCT01504399
- Where
- 4 sites in United States
- Volunteers
- 235 people
- Sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
Nonresectable Adrenocortical Carcinoma
Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC)
The use of Iressa will result in a greater than 20% response rate in patients with nonresectable adrenocortical cancer who have previously been treated with one other form of systemic therapy (either Mitotane or chemotherapy).
- Trial name
- NCT00215202
- Testing
- Iressa (ZD1839)
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Stage IV Adrenocortical Carcinoma
Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer
Current therapies for Stage IV adrenal gland cancer provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of Stage IV adrenal gland…
- Trial name
- NCT00003453
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Burzynski Research Institute
Adrenocortical Carcinoma
Cabazitaxel Activity in Patients With Advanced AdrenoCortical-Carcinoma Progressing After Previous Chemotherapy Lines
Adrenocortical cancer (ACC) is a rare aggressive tumor. The treatment of metastatic ACC is challenging and the current available treatments are mitotane, chemotherapy or the combination of both.
- Trial name
- CabACC (NCT03257891)
- Testing
- Cabazitaxel
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Adrenocortical Carcinoma, Adrenal Cancer
Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma
This first-in-human study is designed to establish the safety and tolerability of ATR-101 in patients with advanced adrenocortical carcinoma whose tumor has progressed on standard therapy.
- Conditions
- Adrenocortical Carcinoma, Adrenal Cancer, ACC
- Trial name
- NCT01898715
- Testing
- ATR-101
- Where
- 5 sites in United States, Germany
- Volunteers
- 63 people
- Sponsor
- Millendo Therapeutics, Inc.
Cushing Syndrome, Adrenocortical Carcinoma
Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma
Adrenocortical Carcinoma (ACC) is an extremely rare disease. Approximately 50% of ACC in adults are functioning leading to hormonal and metabolic syndromes.
- Trial name
- ABACUS (NCT03145285)
- Testing
- Abiraterone Acetate
- Where
- Italy
- Volunteers
- 10 people
- Sponsor
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Adrenocortical Carcinoma
Efficacy of Adjuvant Mitotane Treatment (ADIUVO)
Study Rationale Adrenocortical carcinoma (ACC) is a very rare disease with a high risk of relapse after radical surgery. The efficacy of adjuvant mitotane treatment is suggested by a retrospective multicenter international study…
- Trial name
- ADIUVO (NCT00777244)
- Testing
- MITOTANE
- Where
- 28 sites in United States, Canada and 5 more
- Volunteers
- 200 people
- Sponsor
- University of Turin, Italy
Adrenocortical Carcinoma
Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma
Design: non-randomized, open label, phase II clinical trial. Study population and disease: adult patients with metastatic or locally advanced non-resectable adrenocortical carcinoma, confirmed histologically.
- Trial name
- NCT01514526
- Testing
- Dovitinib
- Where
- 7 sites in Spain
- Volunteers
- 17 people
- Sponsor
- Spanish Oncology Genito-Urinary Group
Adrenocortical Carcinoma, Localized Resectable Neuroblastoma
Natural History Study of Infants With Adrenal Masses Found on Prenatal and/or Neonatal Imaging
This natural history study is collecting health information about infants with adrenal masses found on prenatal and/or neonatal imaging.
- Conditions
- Adrenocortical Carcinoma, Localized Resectable Neuroblastoma, Precancerous Condition
- Trial name
- NCT00445718
- Testing
- computed tomography, 3-Tesla magnetic resonance imaging, Abdominal Sonogram
- Where
- 45 sites in United States, Australia and 1 more
- Volunteers
- 97 people
- Sponsor
- Children's Oncology Group